|
|
 |
|
 |
Phase 1 Investor is our most exclusive and expensive investment advisory at Stansberry Research. Written by our resident biotech expert Rob Fannon, the service primarily focuses on emerging technologies that have a clear and rapid course toward commercialization in the health care, life science, and biotechnology industries.
Rob has considerable experience in business and science, a necessary attribute for an investor in health care and biotechnology. He holds a Masters degree in public health and an MBA, both from Johns Hopkins University. He has also helped open a new biotechnology company in India. Rob's recommendations are some of the best research we've published. His top winners include 203% on Sirna and 215% on ID Biomedical.
To help him out with Phase 1 research, Dr. George Huang joined Rob's team. George's specialty is getting exclusive information from top universities, labs, and venture capital firms on new technologies in the health sector. He holds a Ph.D. from Johns Hopkins' School of Medicine, where he worked under a 2003 Nobel Laureate in chemistry. George also writes our biotech trading service, The S&A FDA Report.
We pay a premium for Rob and George's specialized knowledge. This is why Phase 1 Investor is our most expensive research service, and also why it's so successful.
|
|
|
|
|
|
| ©2010 Stansberry & Associates Investment Research. All Rights Reserved. Protected by copyright laws of the United States and international treaties. This website may only be used pursuant to the subscription agreement and any reproduction, copying, or redistribution (electronic or otherwise, including on the world wide web), in whole or in part, is strictly prohibited without the express written permission of Stansberry & Associates Investment Research, LLC. 1217 Saint Paul Street, Baltimore MD 21202. |
